Wegovy Coverage for Fatty Liver: What to Know in 2026

Meta Description: Find out if your insurance covers Wegovy for fatty liver, what to do if you're denied, and how to build a winning appeal with the right documentation.

Some insurance plans do cover Wegovy for fatty liver disease, but coverage almost always requires prior authorization and specific documentation from your provider. If your plan denies the request, that denial is worth appealing — especially since Wegovy is the only GLP-1 medicine FDA-approved specifically for metabolic dysfunction-associated steatohepatitis (MASH).

Here's the reality: the coverage picture hasn't caught up to the science yet. The FDA approved Wegovy for MASH in August 2025, but many insurers are still running prior authorization workflows that were built around weight management. That gap between what's clinically approved and what's operationally covered is driving a wave of denials that don't hold up when challenged with the right evidence. (If your Wegovy denial is for weight loss rather than MASH, see our Wegovy coverage guide for weight management instead.)

There are real bright spots, though. Medicare now has a clear pathway for Wegovy when it's prescribed for MASH. CVS Caremark, which controls pharmacy benefits for tens of millions of Americans, kept Wegovy as its preferred GLP-1 in mid-2025 — creating a smoother path than many patients expect.

Whether you're trying to figure out if your plan will cover Wegovy before you fill the prescription, or you've already been denied and need to know what to do next, this guide walks through coverage requirements by plan type, the most common denial reasons, and exactly how to build an appeal that addresses each one.

Does Insurance Cover Wegovy for Fatty Liver (MASH)?

Sometimes, yes — but it's rarely automatic.

Coverage generally depends on whether Wegovy is on your plan's formulary, whether you've met your deductible, whether you meet your plan's prior authorization requirements, and whether the correct documentation is submitted with the initial request. That's a lot of "whethers," and each one is a point where things can go sideways without the right preparation.

Here's why the MASH indication matters so much: Wegovy (semaglutide 2.4 mg) is an injection FDA-approved to treat noncirrhotic MASH with moderate-to-advanced fibrosis (stages F2 to F3) in adults, used alongside diet and physical activity. It's the first and only GLP-1 therapy with FDA approval for MASH. That distinction is the foundation of most successful appeals — because even if your plan restricts GLP-1 coverage for weight loss, there may still be a clear path to get Wegovy covered for a liver disease.

One important thing to flag upfront: "fatty liver" is a broad term, and that matters more than you'd think. Wegovy's liver indication is specifically for MASH (metabolic dysfunction-associated steatohepatitis), not general fatty liver disease (MASLD/NAFLD), and it requires documented fibrosis staging of F2 or F3 without cirrhosis. If the documentation submitted to your insurer only says "fatty liver" without the MASH diagnosis and staging, reviewers will often deny simply because they can't confirm you meet the labeled criteria. That's not a judgment call about your health — it's a documentation gap that's entirely fixable.

What Insurers Typically Require for Coverage

Requirements vary by plan, but these are the most common things insurance wants to see before approving Wegovy for MASH. Call your insurance company or visit your member portal for your plan's specific criteria.

MASH diagnosis with fibrosis staging. Plans look for confirmed MASH (not just "fatty liver") with fibrosis stage F2 or F3, documented via biopsy or accepted noninvasive tests like FibroScan (vibration-controlled transient elastography) or MRE (magnetic resonance elastography). Some policies specify the test must be within a defined timeframe, such as the last 180 days.

Confirmation of noncirrhotic status. The FDA approval is specifically for noncirrhotic MASH. Documentation should confirm the absence of cirrhosis and rule out other excluded liver disease causes.

Provider specialty. Some plans require the prescription to be written by, or in consultation with, a gastroenterologist or hepatologist. Check your plan's specific criteria — this requirement catches people off guard.

Correct diagnosis coding. The Wegovy prescription should be coded under MASH (ICD-10 code K75.81) as the primary diagnosis, not obesity. This is a surprisingly common reason for preventable denials. If your prescription gets coded under an obesity diagnosis, you may trigger a weight-loss exclusion that has nothing to do with why you were actually prescribed the medication.

Adult age threshold. Most plans require documentation that the patient is 18 or older, consistent with the FDA approval.

A surprising number of denials happen not because the patient doesn't qualify, but because the right information exists in their medical records and simply isn't included in the PA submission — or isn't easy for the reviewer to locate. This is especially true for fibrosis staging reports. The evidence is there. It just needs to be in front of the right person, in the right format, at the right time.

The CVS Caremark Situation: An Advantage for Wegovy Patients

Unlike some other GLP-1s, Wegovy is in a strong position with CVS Caremark. Effective July 1, 2025, CVS Caremark made Wegovy the preferred GLP-1 on its Standard Control, Advanced Control, and Value formularies — the most common commercial formularies in the country.

For patients with CVS Caremark pharmacy benefits, this generally means easier PA approval for Wegovy compared to other GLP-1s, and often no step therapy requirement when prescribed for a covered indication. If your pharmacy benefits are managed by CVS Caremark, that's a meaningful advantage worth knowing about.

That said, preferred status on CVS Caremark's template formularies doesn't guarantee approval for MASH. Individual employer plans can still layer on their own coverage rules, and the PA criteria for the MASH indication may be different from — and newer than — the criteria for weight loss. Some employer plans also exclude GLP-1 coverage entirely, even when the PBM's template formulary includes them. (If you're dealing with a CVS Caremark denial related to the broader GLP-1 formulary shakeup, our guide to CVS Caremark GLP-1 denials covers that in detail.) The takeaway: check your specific plan, not just your PBM.

Medicare Coverage for Wegovy and MASH

Medicare Part D may cover Wegovy when prescribed specifically for MASH in adults. Medicare does not cover Wegovy for weight loss alone under current federal law, but the August 2025 MASH approval created a new coverage pathway alongside the existing cardiovascular indication (approved March 2024). Whether you're covered depends on whether your specific Part D plan has added Wegovy for MASH to its formulary — check using the Medicare.gov Plan Finder or call the number on your card. Prior authorization is almost always required, and Medicare Advantage plans vary in whether they've added MASH coverage. Note that the Medicare GLP-1 Bridge program launching in July 2026 covers Wegovy and certain other GLP-1s for weight loss only (through December 31, 2027, at a $50/month copay that does not count toward the Part D out-of-pocket cap) and does not apply to the MASH indication, so if you're prescribed Wegovy for MASH, your coverage path is through your Part D plan's standard formulary and appeal process. If your plan denies coverage, Medicare Part D has its own escalation path: redetermination within 60 days, then reconsideration by an Independent Review Entity (IRE), then ALJ hearing. The 2026 annual out-of-pocket cap for Part D is $2,100, and Novo Nordisk savings cards are not available to government-insured patients (Medicare, Medicaid, Tricare).

Common Denial Reasons and What to Do About Each One

When it comes to Wegovy for MASH, nearly every common denial reason can be challenged. The key is matching your response to the specific reason stated in your denial letter. Look for language under "why your request was denied" — that tells you exactly which playbook to follow.

Need help figuring out which reason applies to you and what strategy to use? Use Claimable's guided appeals tool to make it easy.

Prior Authorization Incomplete / Missing Documentation

What it looks like: "Insufficient information," "missing documentation," "clinical records not provided."

What to do: Contact your prescriber's office to find out exactly what was submitted. Compare it against your plan's requirements, then resubmit with a complete packet: MASH diagnosis, fibrosis staging report (FibroScan, MRE, or biopsy), confirmation of noncirrhotic status, and clinical rationale tied to the plan's criteria. The fibrosis staging report is the single most commonly missing document — make sure it's attached and easy to find. This isn't a rejection of your claim. It's a documentation gap, and it's the most straightforward denial to fix.

"Not Medically Necessary"

What it looks like: "Does not meet criteria," "not medically necessary."

What to do: Don't let that phrase intimidate you. "Not medically necessary" almost never means your doctor is wrong — it means the reviewer didn't see enough documentation to check the boxes on their criteria sheet. Get a copy of your plan's coverage criteria and compare it against your records point by point. File an appeal that directly addresses each criterion, especially noncirrhotic MASH with F2 to F3 fibrosis, and include a letter of medical necessity from your healthcare provider. Cite the specific test report page that confirms your staging. If your insurer's criteria don't align with FDA labeling or AASLD (American Association for the Study of Liver Diseases) clinical guidelines, flag that discrepancy in the appeal — it strengthens your case significantly.

Not on Formulary

What it looks like: "Not covered," "non-formulary," "preferred alternatives required."

What to do: Appeal and request a formulary exception. This is where Wegovy's unique position works strongly in your favor: it's the only GLP-1 approved for MASH. If the plan is suggesting another GLP-1 like Zepbound or Ozempic as an alternative, those drugs are not FDA-approved for MASH. That's not a matter of preference — it's a matter of labeled indication. A formulary exception typically requires your prescriber to submit a supporting statement explaining why the non-formulary medication is medically necessary for your specific condition.

Plan Exclusion / "Weight Loss Only"

What it looks like: "Plan excludes weight-related medications," "not a covered benefit."

What to do: This is one of the most frustrating denial types because it's fundamentally a mis-categorization. Wegovy prescribed for MASH is a treatment for liver disease, not a weight-loss prescription. Confirm with your provider that the PA was submitted under ICD-10 code K75.81 (MASH), not obesity (E66.x). If the coding was correct and the denial still cites a weight-loss exclusion, appeal and clearly distinguish between the two indications. Include your fibrosis staging documentation to make the MASH indication unambiguous. Insurers shouldn't be applying a weight-management exclusion to a liver disease, but some are — and appeals that clearly reframe the clinical picture have strong grounds.

Step Therapy / Alternative Required

What it looks like: "Must try X first," "step edit."

What to do: MASH now has another FDA-approved treatment option — resmetirom (Rezdiffra), approved in March 2024 for noncirrhotic MASH with F2 to F3 fibrosis. Some plans may require a trial of Rezdiffra before approving Wegovy, or may ask for clinical justification for choosing Wegovy over the alternative.

If you've already tried other treatments (Rezdiffra, lifestyle interventions, other medications for comorbidities), document those attempts in your appeal. If Rezdiffra isn't appropriate for your clinical situation — for example, due to contraindications, cost, or coexisting conditions where Wegovy's metabolic benefits are clinically relevant — have your prescriber explain that rationale directly.

Additionally, many states have step therapy protection laws that may limit your insurer's ability to enforce step therapy requirements. Check your state's specific protections — they exist for exactly this kind of situation.

How to Appeal a Wegovy MASH Denial

Most people can reverse a Wegovy denial for MASH when they appeal with the right argument, documentation, and clinical backing. The process is more straightforward than most patients expect — and filing the appeal yourself, rather than leaving it solely to your provider, often gives you stronger legal protections and more control over the timeline.

Your appeal should mirror the denial reason. Quote the denial reason directly, respond with the specific evidence that addresses it, and attach supporting documents with the relevant sections highlighted or flagged. Key documents to include: your denial letter, fibrosis staging report (FibroScan, MRE, or biopsy summary), MASH diagnosis notes, confirmation of noncirrhotic status, relevant clinic notes, and — strongly recommended — a letter of medical necessity from your prescribing provider.

Important deadline: Most commercial plans give you 180 days from the denial date to submit an internal appeal. Medicare Part D patients have 60 days. Mark the date and don't let it slip.

If your first appeal is denied, you can request a second-level internal appeal. After exhausting internal appeals, most plans are required by law to offer access to external review through an independent organization — and the insurer is bound by that decision. Your final denial letter should include instructions on how to request it.

How to Get Ahead of a Denial Before It Happens

If your doctor is considering prescribing Wegovy for MASH, you don't have to wait for a denial to start preparing. A little legwork upfront can save weeks of back-and-forth later.

What to ask your insurer (call the number on your insurance card): Is Wegovy covered for MASH under my specific plan? Is it on formulary, and if not, what's the exception process? What are the prior authorization criteria, and where is the PA form? What fibrosis staging methods does the plan accept (FibroScan, MRE, biopsy)? Is a hepatologist or gastroenterologist required to prescribe or co-sign? Where should the PA be submitted (portal or fax)? What are typical timelines, and what qualifies for an expedited review?

What to confirm with your provider before the PA is submitted: Fibrosis staging report is attached (F2 or F3 confirmed). Noncirrhotic status is explicitly documented. Diagnosis is coded under MASH (K75.81), not obesity. Clinical rationale ties directly to the plan's stated criteria. Submission goes to the correct portal or fax number.

Getting these details right the first time doesn't guarantee approval, but it removes the most common reasons insurers use to send you back to square one.

How Claimable Helps

Navigating insurance appeals is time-consuming and confusing — especially when you're dealing with a condition that could progress if coverage drags on. Claimable's appeals tool helps you identify the most likely reason behind your denial, build a customized appeal letter backed by clinical evidence, policy analysis, and relevant legal protections, automatically mail and fax your appeal to the right place, and escalate to the next level if your first appeal is denied.

Start your Wegovy MASH appeal with Claimable →

FAQs

Does insurance cover Wegovy for fatty liver (MASH)?Some plans do, but coverage typically requires prior authorization. Your provider will need to submit documentation including your MASH diagnosis, fibrosis staging (F2 to F3), and confirmation of noncirrhotic status. If your plan denies coverage, you have the right to appeal.

What do I do if insurance denies Wegovy for fatty liver?Get your denial letter and identify the specific reason. Common reasons include missing documentation, "not medically necessary," formulary exclusion, benefit exclusion, or step therapy requirements. File an appeal that directly addresses the stated denial reason with supporting evidence — particularly fibrosis staging documentation.

Why did insurance deny Wegovy for fatty liver?Common reasons include missing PA documentation, inability to confirm MASH with F2 to F3 fibrosis staging, non-formulary status, or the request being processed under a broad GLP-1/weight loss exclusion instead of a liver indication.

Does Medicare cover Wegovy for fatty liver?Medicare Part D may cover Wegovy when prescribed for MASH, since it now has an FDA-approved liver indication. Medicare does not cover Wegovy for weight loss alone. Coverage depends on whether your specific Part D plan has added Wegovy for the MASH indication to its formulary. Note that the Medicare GLP-1 Bridge program (launching July 2026) covers GLP-1s for weight loss only and does not apply to the MASH indication.

Does CVS Caremark cover Wegovy for MASH?As of July 1, 2025, Wegovy is CVS Caremark's preferred GLP-1 on its standard formularies. This generally means easier PA approval, though individual employer plans can still apply their own rules and MASH-specific PA criteria may apply.

Can I appeal a plan exclusion denial for Wegovy for MASH?In many cases, yes. Most benefit exclusions apply to weight-loss medications. Since Wegovy is FDA-approved for MASH, a prescription for liver disease should not fall under a weight-loss exclusion. Appeal and clearly distinguish between the MASH and weight-loss indications.

What is a formulary exception?A formulary exception is a request for coverage of a medication that isn't on your plan's list of covered drugs. For Wegovy and MASH, the exception argument is particularly strong because no other GLP-1 has FDA approval for MASH.

How long do I have to file an appeal?Most commercial plans give you 180 days. Medicare Part D patients have 60 days to request a redetermination. Check your denial letter for exact deadlines.

What clinical evidence supports Wegovy for MASH?The ESSENCE trial showed that 63% of patients on Wegovy achieved MASH resolution compared to 34% on placebo, and 37% had improvement in liver fibrosis compared to 22% on placebo. This was the basis for the FDA's August 2025 approval.

What's the difference between MASH and fatty liver?Fatty liver (MASLD, previously NAFLD) is the broader condition, referring to fat buildup in the liver. MASH (metabolic dysfunction-associated steatohepatitis, previously NASH) is a more advanced stage where fat buildup causes inflammation and liver cell damage, which can progress to fibrosis or cirrhosis. Wegovy is approved specifically for MASH with F2 to F3 fibrosis, not for general fatty liver.

‍